Fredericksen Comments on Trump Team’s Efforts to Screen Records Seized From Lawyer
April 16, 2018
CNN
Partner Scott Fredericksen was quoted in a CNN interview, “President’s Lawyer Reveals His Secret Client Is Sean Hannity,” about a request by President Trump’s team to review records seized from the president’s lawyer to screen out material that may be protected by the attorney client privilege.
Fredericksen likened the president’s intervention in the case to a “bottom of the ninth” play. “The evidence that may be at stake here the government has seized, a federal judge has allowed that so far, could be absolutely toxic to Mr. [Michael] Cohen and perhaps to Mr. Trump and that’s why this is so critical,” he said.
Fredericksen also said Trump would have a hard time shutting down the investigation of his lawyer. “Unless you’re going to fire the entire leadership [of the Justice Department], you can’t shut this down,” he said.
Fredericksen likened the president’s intervention in the case to a “bottom of the ninth” play. “The evidence that may be at stake here the government has seized, a federal judge has allowed that so far, could be absolutely toxic to Mr. [Michael] Cohen and perhaps to Mr. Trump and that’s why this is so critical,” he said.
Fredericksen also said Trump would have a hard time shutting down the investigation of his lawyer. “Unless you’re going to fire the entire leadership [of the Justice Department], you can’t shut this down,” he said.
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."